360biolabs, a BioAgilytix company

360biolabs is Australia's most comprehensive bioanalytical laboratory, providing a diverse range of assay services to support clinical trials programs of new therapeutics, vaccines and diagnostics in a quality-assured environment. We offer a full suite of pharmacokinetic (PK) and pharmacodynamic (PD) endpoints, including small and large molecule PK, ADA, nAb, biomarkers (MSD, ELISA, SIMOA, Luminex, ELISpot), flow cytometry, immunology, molecular and virology assays, supported by globally recognised quality systems under GLP, GCP and ISO/IEC 17025. With a decade of Enabling Future Medicines, 360biolabs has built world-class bioanalytical excellence advancing global clinical research.

360biolabs is pleased to announce the opening of our new laboratory in Sydney, New South Wales! Located in North Ryde within the Macquarie Park Innovation District, the new facility expands our Australian laboratory network and brings established bioanalytical capability closer to clinical research activity in NSW. The Sydney laboratory supports time-sensitive clinical samples where proximity, processing speed and scientific oversight are critical. Capabilities include BSL-2 laboratory space, PBMC isolation, flow cytometry, dedicated sample reception and storage, 24/7 temperature monitoring, ULT freezer capacity and vapour-phase nitrogen cryostorage. The facility has achieved NATA accreditation for compliance with ISO/IEC 17025 and operates under the same procedures, policies and quality standards as our broader Australian network. This is an important step in the continued growth of 360biolabs across Australia, strengthening our ability to support current clients and future studies from Melbourne, Brisbane and now Sydney.

Australia as a first-in-human location. Start your early-phase clinical study with our full suite of Pharmacokinetic and Pharmacodynamic assays for conducting clinical trials. Program success begins in Australia, with expansion to our global sites US/EU for phase 2+.

Every sample counts. The Australian advantage plus 360biolabs means globally validated data and seamless assay transfer to US/EU for continued phase 2+ studies.

Global biotech leaders are strategically choosing Australia to start and accelerate their early clinical study programs. 360biolabs bioanalytical expertise is trusted worldwide to produce and deliver our wide range of comprehensive capabilities from PK, PD, Immunogenicity, Virology and more.

Leverage the Australian Advantage and 360biolabs bioanalytical expertise. Strategically position your next study in Australia with its fast regulatory environment, saving biotech 6-12 months off their clinical timeline. Globally excepted data, accelerate your next early-phase study.